Get him started with a clear dosing plan

An important part of starting treatment with AndroGel 1.62% is ensuring he is initiated on the proper starting dose and then establishing a clear monitoring plan for dose adjustment.

Review dosage instructions and precautions

For patients diagnosed with hypogonadism due to an associated medical condition, the recommended starting dose is 40.5 mg—applied once daily in the morning to the shoulder(s) and upper arm(s). Instruct patients not to apply AndroGel 1.62% to any other parts of the body, including the abdomen, genitals, chest, armpits (axillae), or knees. The application sites and dosage of AndroGel 1.62% are not interchangeable with other topical testosterone replacement products.1

Applying AndroGel 1.62%

Use the application video to help patients understand the proper application and safety precautions of AndroGel 1.62%. Direct them to AndroGelApplication.com

Accurate dose measurement with pump and packets

The total dose of testosterone can be adjusted between 20.25 mg and 81 mg in 20.25 mg increments based on the patient's response to therapy. AndroGel 1.62% is available in a metered-dose pump or travel-ready packets.1

AndroGel 1.62% Dosing Conversion Chart1
20.25 mg

Pump:

One pump actuation (once daily) in the morning

Packets:

One 20.25 mg packet (once daily) in the morning

40.5 mg
Recommended Starting Dose

Pump:

Two pump actuations (once daily) in the morning

Packets:

One 40.5 mg packet (once daily) in the morning

60.75 mg

Pump:

Three pump actuations (once daily) in the morning

Packets:

One 40.5 mg packet and one 20.25 mg packet (once daily) in the morning

81 mg

Pump:

Four pump actuations (once daily) in the morning

Packets:

Two 40.5 mg packets (once daily) in the morning

AndroGel 1.62% dosing depends on testosterone levels and symptoms.

Make sure he's taking the right dose

Testosterone levels should be checked at 14 and 28 days after starting treatment and periodically thereafter.1

Safety Considerations1

  • Avoid unintentional exposure of women or children to AndroGel 1.62%. Secondary exposure to testosterone can produce signs of virilization. Exposure of a pregnant woman to AndroGel may result in potential hazard to the fetus. AndroGel 1.62% should be promptly discontinued until the cause of virilization is identified.